Targeted Tissue and Cell‐Free Tumor DNA Sequencing of Advanced Lung Squamous‐Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations

[1]  K. Syrigos,et al.  Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial , 2018, JAMA oncology.

[2]  C. Paweletz,et al.  Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies , 2018, Clinical Cancer Research.

[3]  B. Sundaram,et al.  Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecula , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Mortimer,et al.  The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients , 2017, Clinical Cancer Research.

[5]  Moriah H Nissan,et al.  OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.

[6]  F. Meric-Bernstam,et al.  Targeting TRK family proteins in cancer , 2017, Pharmacology & therapeutics.

[7]  Ross Camidge,et al.  Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Lisa M McShane,et al.  Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial. , 2017, The Journal of molecular diagnostics : JMD.

[9]  Mary E Reid,et al.  The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  Anil Vachani,et al.  Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA , 2016, Clinical Cancer Research.

[11]  P. Stephens,et al.  Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  C. Rolfo,et al.  B-RAF mutation in non-small cell lung cancer: the sleeping beauty is waking up. , 2016, Translational lung cancer research.

[13]  S. Mortimer,et al.  Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA. , 2016 .

[14]  O. Harismendy,et al.  Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients , 2016, Clinical Cancer Research.

[15]  Chandra Sekhar Pedamallu,et al.  Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas , 2016, Nature Genetics.

[16]  Yoon-La Choi,et al.  ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare. , 2016, Lung cancer.

[17]  P. Jänne,et al.  MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  B. Kermani,et al.  Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA , 2015, PloS one.

[19]  J. Austin,et al.  The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  K. Syrigos,et al.  Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. , 2015, The Lancet. Oncology.

[21]  C. Schumann,et al.  Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. , 2015, The Lancet. Oncology.

[22]  N. Schultz,et al.  Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. , 2015, Cancer discovery.

[23]  David Wholley,et al.  Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400 , 2015, Clinical Cancer Research.

[24]  Jiandong Wang,et al.  Detection of ALK protein expression in lung squamous cell carcinomas by immunohistochemistry , 2014, Journal of experimental & clinical cancer research : CR.

[25]  M. Ladanyi,et al.  Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  A. Nicholson,et al.  Reproducibility of Histopathological Diagnosis in Poorly Differentiated NSCLC: An International Multiobserver Study , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  Andreas Sashegyi,et al.  Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial , 2014, The Lancet.

[28]  A. Iafrate,et al.  Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). , 2014 .

[29]  Rashmi Kanagal-Shamanna,et al.  Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. , 2013, The Journal of molecular diagnostics : JMD.

[30]  Yi-long Wu,et al.  Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap) , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[32]  H. Ji,et al.  RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[34]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[35]  M. Ladanyi,et al.  Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations , 2012, Clinical Cancer Research.

[36]  Ping Yang,et al.  Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. , 2009, Human pathology.

[37]  Susanna M Cramb,et al.  The International Epidemiology of Lung Cancer: Geographical Distribution and Secular Trends , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[38]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.